Syndax Pharmaceuticals, Inc.
SNDX
$23.91
$0.411.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 163.24M | 102.19M | 68.82M | 43.72M | 23.68M |
| Total Other Revenue | 9.36M | 9.36M | 9.36M | -- | -- |
| Total Revenue | 172.60M | 111.55M | 78.18M | 43.72M | 23.68M |
| Cost of Revenue | 204.12M | 189.13M | 201.72M | 186.87M | 185.98M |
| Gross Profit | -31.52M | -77.58M | -123.54M | -143.14M | -162.30M |
| SG&A Expenses | 180.08M | 167.74M | 153.93M | 139.19M | 121.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 445.84M | 418.51M | 417.29M | 387.69M | 363.65M |
| Operating Income | -273.24M | -306.95M | -339.11M | -343.97M | -339.97M |
| Income Before Tax | -285.82M | -311.88M | -335.29M | -331.50M | -319.06M |
| Income Tax Expenses | -400.00K | -300.00K | -300.00K | -300.00K | -300.00K |
| Earnings from Continuing Operations | -285.42 | -311.58 | -334.99 | -331.20 | -318.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -285.42M | -311.58M | -334.99M | -331.20M | -318.76M |
| EBIT | -273.24M | -306.95M | -339.11M | -343.97M | -339.97M |
| EBITDA | -273.23M | -306.95M | -339.10M | -343.96M | -339.96M |
| EPS Basic | -3.30 | -3.62 | -3.90 | -3.87 | -3.73 |
| Normalized Basic EPS | -2.07 | -2.26 | -2.44 | -2.42 | -2.33 |
| EPS Diluted | -3.30 | -3.62 | -3.90 | -3.87 | -3.73 |
| Normalized Diluted EPS | -2.07 | -2.26 | -2.44 | -2.42 | -2.33 |
| Average Basic Shares Outstanding | 346.04M | 344.92M | 343.73M | 342.67M | 341.71M |
| Average Diluted Shares Outstanding | 346.04M | 344.92M | 343.73M | 342.67M | 341.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |